Theriva Biologics Q2 EPS $(0.43) Misses $(0.19) Estimate
Portfolio Pulse from Benzinga Newsdesk
Theriva Biologics (AMEX:TOVX) reported a Q2 EPS of $(0.43), missing the analyst consensus estimate of $(0.19) by 126.32%. This represents a 26.47% increase in losses compared to the same period last year.
August 13, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Theriva Biologics reported a Q2 EPS of $(0.43), significantly missing the analyst consensus estimate of $(0.19) by 126.32%. This marks a 26.47% increase in losses compared to the same period last year.
The significant miss on EPS estimates and the increase in losses compared to the previous year are likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100